313 related articles for article (PubMed ID: 25498909)
1. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.
Kim YC; Zhang AH; Su Y; Rieder SA; Rossi RJ; Ettinger RA; Pratt KP; Shevach EM; Scott DW
Blood; 2015 Feb; 125(7):1107-15. PubMed ID: 25498909
[TBL] [Abstract][Full Text] [Related]
2. CD4
Fu RY; Chen AC; Lyle MJ; Chen CY; Liu CL; Miao CH
Cell Immunol; 2020 Dec; 358():104216. PubMed ID: 32987195
[TBL] [Abstract][Full Text] [Related]
3. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.
Yoon J; Schmidt A; Zhang AH; Königs C; Kim YC; Scott DW
Blood; 2017 Jan; 129(2):238-245. PubMed ID: 28064157
[TBL] [Abstract][Full Text] [Related]
4. Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells.
Pohl AP; Venkatesha SH; Zhang AH; Scott DW
Front Immunol; 2020; 11():693. PubMed ID: 32373126
[TBL] [Abstract][Full Text] [Related]
5. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.
Miao CH; Harmeling BR; Ziegler SF; Yen BC; Torgerson T; Chen L; Yau RJ; Peng B; Thompson AR; Ochs HD; Rawlings DJ
Blood; 2009 Nov; 114(19):4034-44. PubMed ID: 19713458
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice.
Smith BM; Lyle MJ; Chen AC; Miao CH
J Thromb Haemost; 2020 Feb; 18(2):328-340. PubMed ID: 31609041
[TBL] [Abstract][Full Text] [Related]
7. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
Liu CL; Ye P; Lin J; Djukovic D; Miao CH
J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
[TBL] [Abstract][Full Text] [Related]
8. Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells.
Zhang AH; Yoon J; Kim YC; Scott DW
J Immunol; 2018 Sep; 201(5):1434-1441. PubMed ID: 30021767
[TBL] [Abstract][Full Text] [Related]
9. Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.
Parvathaneni K; Abdeladhim M; Pratt KP; Scott DW
Transl Res; 2017 Sep; 187():44-52. PubMed ID: 28651073
[TBL] [Abstract][Full Text] [Related]
10. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
[TBL] [Abstract][Full Text] [Related]
11. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
Liu CL; Ye P; Yen BC; Miao CH
Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
[TBL] [Abstract][Full Text] [Related]
12. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
13. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
14. Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.
Su RJ; Epp A; Latchman Y; Bolgiano D; Pipe SW; Josephson NC
Mol Ther; 2010 Jan; 18(1):214-22. PubMed ID: 19755963
[TBL] [Abstract][Full Text] [Related]
15. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
[TBL] [Abstract][Full Text] [Related]
16. Reprogrammed CD4
Herzog RW; Kuteyeva V; Saboungi R; Terhorst C; Biswas M
Front Immunol; 2019; 10():274. PubMed ID: 30842776
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.
Waters B; Qadura M; Burnett E; Chegeni R; Labelle A; Thompson P; Hough C; Lillicrap D
Blood; 2009 Jan; 113(1):193-203. PubMed ID: 18815284
[TBL] [Abstract][Full Text] [Related]
19. CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII.
Rana J; Perry DJ; Kumar SRP; Muñoz-Melero M; Saboungi R; Brusko TM; Biswas M
Mol Ther; 2021 Sep; 29(9):2660-2676. PubMed ID: 33940160
[TBL] [Abstract][Full Text] [Related]
20. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.
Becker-Gotot J; Meissner M; Kotov V; Jurado-Mestre B; Maione A; Pannek A; Albert T; Flores C; Schildberg FA; Gleeson PA; Reipert BM; Oldenburg J; Kurts C
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36107620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
